Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,374,090	$ 5,794,272
Short-term investment securities	5,362,635	6,847,270
Interest receivable	30,078	58,285
Accounts receivable	754,098	330,001
Prepaid expenses and other current assets	284,597	392,236
Total current assets	12,805,498	13,422,064
Non-current assets:
Investment in Alphazyme	0	284,709
Other assets	6,065	6,045
Total assets	12,811,563	13,712,818
Current liabilities:
Accounts payable	770,371	1,276,313
Accrued expenses	863,041	955,081
Deferred research and development obligations	65,207	40,743
Deferred license revenue, current portion	176,471	176,471
Total current liabilities	1,875,090	2,448,608
Deferred license revenue, net of current portion	132,353	176,471
Total liabilities	2,007,443	2,625,079
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding	0	0
Common stock, $.001 par value:Authorized shares - 100,000,000; issued shares - 40,332,659 and 39,747,659, outstanding shares - 28,079,157 and 27,494,157 as of June 30, 2021, and December 31, 2020, respectively	41,065	40,817
Additional paid-in capital	104,131,274	103,458,697
Treasury stock, shares held at cost - 12,253,502	(18,929,915)	(18,929,915)
Accumulated deficit	(74,438,304)	(73,481,860)
Total stockholders’ equity	10,804,120	11,087,739
Total liabilities and stockholders’ equity	$ 12,811,563	$ 13,712,818